MedPath

Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.

Recruiting
Conditions
SARS-CoV-2
Interventions
Biological: SPIKEVAX X
Registration Number
NCT06333704
Lead Sponsor
ModernaTX, Inc.
Brief Summary

The main objective of the surveillance is to evaluate the incidence of the adverse events (AEs), and other safety related information in South-Korean population.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
4206
Inclusion Criteria
  • Participants should be 18 years or older for Spikevax bivalent BA.1, SPIKEVAX BIVALENT BA.4/5 vaccine, and 12 years or older for Spikevax XBB.1.5 injection.
  • Participants of any age which is approved for the use of SPIKEVAX BIVALENT BA.1, SPIKEVAX BIVALENT BA.4/5 or SPIKEVAX XBB.1.5 for active immunization to prevent COVID-19 caused by SARS-CoV-2.
  • Participant who will be vaccinated with SPIKEVAX BIVALENT BA.1, SPIKEVAX BIVALENT BA.4/5 or SPIKEVAX XBB.1.5 following local label approved by Ministry of Food and Drug Safety (MFDS).
  • Participant who will be vaccinated with at least one dose of SPIKEVAX BIVALENT BA.1, SPIKEVAX BIVALENT BA.4/5 or SPIKEVAX XBB.1.5.
Exclusion Criteria
  • Participant whose participation is deemed inappropriate at the investigator's discretion.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
SPIKEVAX BIVALENT or SPIKEVAX XSPIKEVAX BivalentParticipants receiving at least 1 dose of SPIKEVAX BIVALENT vaccine or SPIKEVAX X Injection are monitored for safety parameters up to 28 days post vaccination.
SPIKEVAX BIVALENT or SPIKEVAX XSPIKEVAX XParticipants receiving at least 1 dose of SPIKEVAX BIVALENT vaccine or SPIKEVAX X Injection are monitored for safety parameters up to 28 days post vaccination.
Primary Outcome Measures
NameTimeMethod
Number of Participants With AEsUp to 28 days post vaccination
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (24)

Sinsegie ENT Clinic

🇰🇷

Busan, Korea, Republic of

Kium Children Hospital

🇰🇷

Gunsan, Jeollabuk-do, Korea, Republic of

Jeil Family Medicine Clinic

🇰🇷

Gwangju, Korea, Republic of

Yonsei Kids Pediatrics Clinic

🇰🇷

Seoul, Korea, Republic of

Seoul Bon Clinic

🇰🇷

Seoul, Korea, Republic of

GF Pediatrics Clinic

🇰🇷

Seoul, Korea, Republic of

Joon Pediatric Clinic

🇰🇷

Gwangmyeong, Gyeonggi-do, Korea, Republic of

Hanyang Union Rehabilitation Medicine Clinic

🇰🇷

Yangju, Gyeonggi-do, Korea, Republic of

KimHyungjoo Clinic

🇰🇷

Yangju, Gyeonggi-do, Korea, Republic of

Woori Medical Clinic

🇰🇷

Seoul, Korea, Republic of

Nalee Hospital

🇰🇷

Gimpo, Gyeonggi-do, Korea, Republic of

Janghyeon Medicine Clinic

🇰🇷

Siheung, Gyeonggi-do, Korea, Republic of

Star Pediatrics Clinic

🇰🇷

Seoul, Korea, Republic of

Ma Hak ki Family Medicine Clinic

🇰🇷

Bucheon, Gyeonggi-do, Korea, Republic of

Yonseimin Clinic

🇰🇷

Wonju, Gangwon-do, Korea, Republic of

Hyundai Clinic

🇰🇷

Bucheon, Gyeonggi-do, Korea, Republic of

COA ENT Clinic

🇰🇷

Goyang, Gyeonggi-do, Korea, Republic of

Bupyeong Yonsei Medical Clinic

🇰🇷

Incheon, Korea, Republic of

Inha University Hospital

🇰🇷

Incheon, Korea, Republic of

Dr Cho's Family Medical Clinic

🇰🇷

Seoul, Korea, Republic of

Songpa Korea Neurosurgical Clinic

🇰🇷

Seoul, Korea, Republic of

New Yonsei ENT Clinic

🇰🇷

Seoul, Korea, Republic of

Kim Il Joong Internal Medicine Clinic

🇰🇷

Seoul, Korea, Republic of

Soo Orthopedics Clinic

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath